New molecular targets for antianxiety interventions

Journal of Clinical Psychiatry

Volumn 64, Issue SUPPL. 3, 2003, Pages 28-35

  Gorman, Jack M ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 (4,4 DIPHENYL 3 BUTENYL)NIPECOTIC ACID; 3 (6 DIMETHYLAMINO 4 METHYL 3 PYRIDINYL) 7 DIPROPYLAMINO 2,5 DIMETHYLPYRAZOLO[1,5 A]PYRIMIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID A RECEPTOR; 4 AMINOBUTYRIC ACID RECEPTOR BLOCKING AGENT; 4 AMINOBUTYRIC ACID RECEPTOR STIMULATING AGENT; 5 [[2 [1 [3,5 BIS(TRIFLUOROMETHYL)PHENYL]ETHOXY] 3 (4 FLUOROPHENYL) 4 MORPHOLINYL]METHYL] N,N DIMETHYL 1H 1,2,3 TRIAZOLE 4 METHANAMINE; ALPRAZOLAM; ANXIOLYTIC AGENT; APREPITANT; BENZODIAZEPINE DERIVATIVE; BENZODIAZEPINE RECEPTOR; BRAIN DERIVED NEUROTROPHIC FACTOR; CORTICOTROPIN RELEASING FACTOR; CORTICOTROPIN RELEASING FACTOR ANTAGONIST; DELORAZEPAM; DIAZEPAM; DIZOCILPINE; EGLUMETAD; FLUOXETINE; IMIPRAMINE; KETAMINE; NKP 608; NORADRENALIN; PAGOCLONE; PAROXETINE; PREGABALIN; SEROTONIN; SUBSTANCE P; SUBSTANCE P ANTAGONIST; TIAGABINE; TRAZODONE; TRIMIPRAMINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VENLAFAXINE; VOFOPITANT;

ANXIETY DISORDER; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; GABAERGIC SYSTEM; HUMAN; LIVER TOXICITY; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; REVIEW; SOMNOLENCE; VERTIGO;

ANTI-ANXIETY AGENTS; ANXIETY DISORDERS; BENZODIAZEPINES; CLINICAL TRIALS; GABA AGENTS; HUMANS; NERVE GROWTH FACTORS; NOREPINEPHRINE; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; RECEPTORS, GABA; RECEPTORS, GABA-A; RECEPTORS, N-METHYL-D-ASPARTATE; RECEPTORS, NEUROKININ-1; SEROTONIN; SEROTONIN AGENTS; TREATMENT OUTCOME;

EID: 0037240648     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Sandford JJ, Forshall S, Bell C, et al. Crossover trial of pagoclone and placebo in patients with DSM-IV panic disorder. J Psychopharmacol 2001; 15:205-208
2. McKernan RM, Rosahl TW, Reynolds DS, et al. Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha 1 subtype. Nat Neurosci 2000;3:587-592
3. Löw K, Crestani F, Keist R, et al. Molecular and neuronal substrate for the selective attenuation of anxiety. Science 2000;290:131-134
4. Rudolph U, Crestani F, Benke D, et al. Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes. Nature 1999;401: 796-800
5. Crane DL. The selective GABA reuptake inhibitor tiagabine for the treatment of anxiety. Presented at the 22nd National Conference of the Anxiety Disorders Association of America; March 21-24, 2002; Austin, Tex
6. Schmitt U, Hiemke C. Effects of GABA-transporter (GAT) inhibitors on rat behaviour in open-field and elevated plus-maze. Behav Pharmacol 1999;10: 131-137
7. Lara ME. Adjunctive use of tiagabine with antidepressants in post-traumatic stress disorder. Presented at the 22nd National Conference of the Anxiety Disorders Association of America; March 21-24, 2002; Austin, Tex
8. Rickels K, Bielski RJ, Feltner DE, et al. Efficacy and safety of pregabalin and alprazolam in generalized anxiety disorder. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association; May 21, 2002; Philadelphia, Pa. Abstract NR162:44
9. Kasper S, Blagden M, Seghers S, et al. A placebo-controlled study of pregabalin and venlafaxine treatment of GAD. In: New Research Abstracts of the 155th Annual Meeting of the American Psychiatric Association; May 21, 2002; Philadelphia, Pa, Abstract NR202:55
10. Rickels K, Downing R, Schweizer E, et al. Antidepressants for the treatment of generalized anxiety disorder: a placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 1993;50: 884-895
11. Rocca P, Fonzo V, Scotta M, et al. Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 1997;95:444-450
12. Pollack MH, Zaninelli R, Goddard A, et al. Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexibledosage trial. J Clin Psychiatry 2001;62:350-357
13. Rickels K, Pollack MH, Sheehan DV, et al. Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 2000;157:968-974
14. Gelenberg AJ, Lydiard RB, Rudolph RL, et al. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month controlled trial. JAMA 2000;283:3082-3088
15. 1A receptor acts during development to establish normal anxiety-like behavior in the adult. Nature 2002;416:396-400
16. Zhuang X, Gross C, Santarelli L, et al. Altered emotional states in knockout mice lacking 5-HT1A or 5-HT1B receptors. Neuropsychopharmacology 1999;21(2 suppl):52S-60S
17. Ramboz S, Oosting R, Amara DA, et al. Serotonin receptor 1A knockout: an animal model of anxiety-related disorder. Proc Natl Acad Sci U S A 1998;95:14476-14481
18. Santarelli L, Saxe MD, Gross C, et al. Role of adult neurogenesis in the behavioral effect of antidepressant. In: 2002 Abstract Viewer/Itinerary Planner [CD-ROM]. Washington, DC: Society for Neuroscience, 2002. Program No. 102.8
19. Rauch SL, Whalen PJ, Shin LM, et al. Exaggerated amygdala response to masked facial stimuli in posttraumatic stress disorder: a functional MRI study. Biol Psychiatry 2000;47:769-776
20. Birbaumer N, Grodd W, Diedrich O, et al. fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 1998;20:1223-1226
21. Asakura M, Nagashima H, Fujii S, et al. Influences of chronic stress on central nervous systems [in Japanese]. Nihon Shinkei Seishin Yakurigaku Zasshi 2000;20:97-105
22. Owens MJ, Nemeroff CB. The role of corticotropin-releasing factor in the pathophysiology of affective and anxiety disorders: laboratory and clinical studies. Ciba Found Symp 1993;172:296-308; discussion 308-316
23. Coplan JD, Goetz R, Klein DF, et al. Plasma cortisol concentrations preceding lactate-induced panic. Arch Gen Psychiatry 1998;55:130-136
24. Bremner JD, Licinio J, Darnell A, et al. Elevated CSF corticotropin-releasing factor concentrations in posttraumatic stress disorder. Am J Psychiatry 1997;154:624-629
25. Keck ME, Welt T, Wigger A, et al. The anxiolytic effects of the CRH(1) receptor antagonist R121919 depends on innate emotionality in rats. Eur J Neurosci 2001;13:373-380
26. Zobel AW, Nickel T, Kunzel HE, et al. Effects of the high-affinity corticotropin-releasing hormone receptor 1 antagonist R121919 in major depression: the first 20 patients treated. J Psychiatr Res 2000;34:171-181
27. Mantyh PW, Hunt SP, Maggio JE. Substance P receptors: localization by light microscopic autoradiography in rat brain using [3H]SP as the radioligand. Brain Res 1984;307(1-2):147-165
28. Unger T, Carolus S, Demmert G, et al. Substance P induces a cardiovascular defense reaction in the rat: pharmacological characterization. Circ Res 1988;63:12-20
29. Krase W, Koch M, Schilitzler HU. Substance P is involved in the sensitization of the acoustic startle response by footshocks in rats. Behav Brain Res 1994;63:81-88
30. Rupniak NM, Carlson EJ, Webb JK, et al. Comparison of the phenotype of NK1R-/- mice with pharmacological blockade of the substance P (NK1) receptor in assays for antidepressant and anxiolytic drugs. Behav Pharmacol 2001;12(6-7):497-508
31. Papp M, Vassout A, Gentsch C. The NK1-receptor antagonist NKP608 has an antidepressant-like effect in the chronic mild stress model of depression in rats. Behav Brain Res 2000;115:19-23
32. Kramer MS, Cutler N, Feighner J, et al. Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science 1998; 281:1640-1645
33. Eriksson PS, Perfilieva E, Bjork-Eriksson T, et al. Neurogenesis in the adult human hippocampus. Nat Med 1998;4:1313-1317
34. Sharma AC, Kulkarni SK. Evidence for benzodiazepine receptor interaction with MK 801 in anxiety related behavior in rats. Indian J Exp Biol 1993;31:191-193
35. Xie Z, Commissaris RL. Anxiolytic-like effects of the noncompetitive NMDA antagonist MK 801. Pharmacol Biochem Behav 1992;43:471-477
36. Trullas R, Skolnick P. Functional antagonists at the NMDA receptor complex exhibit antidepressant actions. Eur J Pharmacol 1990;185:1-10
37. Papp M, Moryl E. New evidence for the antidepressant activity of MK-801, a non-competitive antagonist of NMDA receptors. Pol J Pharmacol 1993; 45:549-553
38. Przegalinski E, Tatarczynska E, Deren-Wesolek A, et al. Antidepressant-like effects of a partial agonist at strychnine-insensitive glycine receptors and a competitive NMDA receptor antagonist. Neuropharmacology 1997; 36:31-37
39. Berman RM, Cappiello A, Anand A, et al. Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000;47:351-354
40. Skolnick P. Antidepressants for the new millennium. Eur J Pharmacol 1999;375:31-40
41. Shekhar A, Keim SR. LY354740, a potent group II metabotropic glutamate receptor agonist prevents lactate-induced panic-like response in panic-prone rats. Neuropharmacology 2000;39:1139-1146
42. Coplan JD, Smith E, Trost R, et al. Effects of LY354740, a novel glutamatergic metabotropic agonist, on nonhuman primate hypothalamic-pituitary adrenal and noradrenergic function. CNS Spectrums 2001;6:607-617
43. Moore GJ, MacMaster FP, Stewart C, et al. Case study: caudate glutamatergic changes with paroxetine therapy for pediatric obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry 1998;37:663-667
44. Shirayama Y, Chen AC, Nakagawa S, et al. Brain-derived neurotrophic factor produces antidepressant effects in behavioral models of depression. J Neurosci 2002;22:3251-3261
45. Chen B, Dowlatshahi D, MacQueen GM, et al. Increased hippocampal BDNF immunoreactivity in subjects treated with antidepressant medication. Biol Psychiatry 2001;50:260-265